GET DAILY SIGNALSWhy Is Waystar Holding Corp. (WAY) Stock Down -5.37% Today?
Key Takeaways
- WAY shares fell roughly 5.37% to around $26.63, down from a prior close of $28.14.
- The primary catalyst was a fiscal 2026 revenue guidance midpoint that landed below Wall Street's consensus, overshadowing an otherwise strong Q3 beat.
- Management flagged a sharp implied slowdown in fourth-quarter revenue growth, driven by longer implementation cycles and revenue-timing effects.
- The selloff extended Monday's after-hours decline, compounded by broader caution across software and growth names.
- Traders are watching how strong bookings convert into recognized revenue and the formal outlook the company issues next quarter.
- For deeper context on valuation and catalysts, explore Price Targets, Earnings, and Forecast pages for WAY.
- To see which strategies are performing best under current conditions, explore Trending AI Robots.
Opening Summary
Waystar Holding Corp. (WAY) is a Lehi, Utah-based provider of cloud software that simplifies healthcare payments and revenue-cycle management for providers across the care continuum. In Tuesday's session, shares were down approximately 5.37%, trading around $26.63 versus a prior closing price of $28.14. The decline extended a post-earnings selloff that began after the company's third-quarter report, as investors focused on revenue guidance that came in below consensus despite better-than-expected quarterly results.
Earnings Results and Guidance
The move was fundamentally earnings-driven. Waystar reported third-quarter revenue of roughly $325.6 million, up 21% year over year, and adjusted earnings per share of $0.44, ahead of the $0.41 analyst consensus. Adjusted EBITDA rose 24% to about $139 million, reflecting a 43% margin, and the company highlighted record demand metrics, including year-to-date bookings growth of 25% and the largest new client win in its history.
Despite the beat, markets zeroed in on the forward view. Waystar narrowed its full-year 2026 revenue guidance to a range of $1.277 billion to $1.287 billion, with a midpoint of $1.282 billion that fell below the roughly $1.29 billion consensus. The implied fourth-quarter revenue growth of approximately 6% represented a marked deceleration from the third quarter's 21% pace, and that gap is what pressured the stock.
Revenue-Timing Headwinds
Management attributed the softer fourth-quarter outlook to three specific factors rather than weakening underlying demand: a faster-than-expected shift from printed to digital patient statements, revenue-timing effects in the Iodine business tied to performance-based pricing, and difficult year-over-year comparisons against unusually fast client implementations in the prior year. Together, these items were expected to reduce fourth-quarter growth by roughly four percentage points.
The company also noted that larger, broader platform deals are taking longer to ramp, with implementation-to-revenue conversion times extending to 12-to-18 months. While management characterized the slowdown as a timing issue rather than a demand problem, the widening gap between strong bookings and recognized revenue weighed on sentiment.
Analyst Reaction
Analyst responses were mixed but largely constructive on the underlying business. Several firms raised price targets while maintaining Buy-equivalent ratings, citing robust bookings growth and a growing implementation backlog. Others trimmed targets to reflect the slower near-term revenue conversion. The divergence highlighted the central tension in the stock: record demand signals colliding with a flattening near-term revenue curve.
Market Context and Trading Activity
The decline in WAY shares was accompanied by elevated trading activity, as the post-earnings repricing attracted meaningful volume. The move also unfolded against a cautious backdrop for growth-oriented software names, with technology shares under pressure amid ongoing concerns about valuations and AI-related spending. This broader risk-off tone amplified the single-stock catalyst rather than offsetting it.
What Comes Next for WAY
Looking ahead, investors will focus on how Waystar's record bookings translate into recognized revenue over the coming quarters. Management indicated it expects to provide additional context on the bookings-to-revenue relationship with its formal outlook next quarter, which could serve as a key catalyst. Risks include prolonged implementation timelines, the continued impact of the print-to-digital statement shift, and execution on the Iodine integration. On the positive side, the company's expanding large-client cohort, strong cash generation, and improving leverage provide a durable foundation if revenue conversion normalizes as guided.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that collectively cover thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a way to observe which automated approaches are adapting best to today's market environment. Explore Trending AI Robots to see which strategies are currently standing out.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
WAY in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 15, 2026
WAY broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 22 similar instances where the stock broke above the upper band. In 18 of the 22 cases the stock fell afterwards. This puts the odds of success at 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for WAY moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In 11 of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 23 of 32 cases where WAY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for WAY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 25 similar instances when the indicator turned negative. In 18 of the 25 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on WAY as a result. In 35 of 44 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +0.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAY advanced for three days, in 110 of 139 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 67 of 79 cases where WAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. WAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.354) is normal, around the industry mean (4.699). P/E Ratio (39.634) is within average values for comparable stocks, (13.248). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement